Status:
NOT_YET_RECRUITING
Acupuncture With/Without Self-acupressure for Post-oophorectomy Hot Flashes in BRCA Carriers
Lead Sponsor:
Shaare Zedek Medical Center
Conditions:
Hot Flashes
Menopause Surgical
Eligibility:
FEMALE
25+ years
Phase:
NA
Brief Summary
Risk-reducing surgery with salpingo-oophorectomy (RRSO) is the standard recommended treatment for all female carriers of BRCA genes 1 and 2. The post-surgical menopause induced is invariably accompani...
Eligibility Criteria
Inclusion
- Female carriers of the BRCA 1 and 2 genes
- age ≥ 25 years
- after risk-reducing salpingo-oophorectomy
- reporting ≥ 5 hot flashes per day
Exclusion
- Patients not fulfilling the study inclusion criteria will be excluded from participation
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05331209
Start Date
January 1 2026
End Date
December 31 2027
Last Update
May 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Integrative Complementary Medicine, Shaare Zedek Medical Center
Jerusalem, Israel, 7791031